Christopher W. Murray and David C. Rees. “The rise of fragment based drug discovery.” Nature Chemistry 1, no. 3 2009: 187-192. DOI: 10.1038/nchem.217.

/in ,

Christopher W. Murray and David C. Rees. “The rise of fragment based drug discovery.” Nature Chemistry 1, no. 3 2009: 187-192. DOI: 10.1038/nchem.217.

Curry J. et al. “Aurora kinase inhibition in mitosis: Strategies for optimising the use of aurora kinase inhibitors such as AT9283.” Cell Cycle 8, no. 12 2009: 1-9. DOI: 10.4161/cc.8.12.8741.

/in ,

Curry J. et al. “Aurora kinase inhibition in mitosis: Strategies for optimising the use of aurora kinase inhibitors such as AT9283.” Cell Cycle 8, no. 12 2009: 1-9. DOI: 10.4161/cc.8.12.8741.

Davies et al. “Fragment-Based Discovery of Inhibitors of Protein Kinase B.” Current Topics in Medicinal Chemistry 9, no. 18 2009: 1705-1717.

/in ,

Davies et al. “Fragment-Based Discovery of Inhibitors of Protein Kinase B.” Current Topics in Medicinal Chemistry 9, no. 18 2009: 1705-1717.

Day et al. “Crystal structure of human CDK4 in complex with a D-type cyclin.” Proceedings of the National Academy of Sciences 106, no. 11 2009: 4166-4170. DOI: 10.1073/pnas.0809645106.

/in ,

Day et al. “Crystal structure of human CDK4 in complex with a D-type cyclin.” Proceedings of the National Academy of Sciences 106, no. 11 2009: 4166-4170. DOI: 10.1073/pnas.0809645106.

Howard et al. “Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi-targeted Kinase Inhibitor with Potent Aurora Kinase Activity.” Journal of Medicinal Chemistry 52, no. 2 2009: 379–388. DOI: 10.1021/jm800984v.

/in ,

Howard et al. “Fragment-Based Discovery of the Pyrazol-4-yl urea (AT9283), a Multi-targeted Kinase Inhibitor with Potent Aurora Kinase Activity.” Journal of Medicinal Chemistry 52, no. 2 2009: 379–388. DOI: 10.1021/jm800984v.